Troutman Pepper represented MVM Partners, a health care investment firm focused on commercial stage companies, in its investment in Gynesonics® Inc., a women’s health care company focused on the development of minimally invasive solutions for symptomatic uterine fibroids. MVM Partners joins Amzak Healthcare, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital in the investment. Read a press release about the financing.

A pioneer in women’s health, Gynesonics focuses on developing and delivering minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Its flagship product, the Sonata System®, is the first FDA-cleared medical device for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, a medical condition affecting roughly 80% of adult women.

The team advising MVM Partners in the financing included Dan Sieck, Chris Miller, and Alicia Worthy.